Drugs for cancer and alcoholism show promise for RP
With all the interest in exciting gene and cell therapies for inherited sight loss, it’s easy to forget that more traditional drugs can also hold promise.
Search
Search results
Work for us
Retina UK employs a team of staff at our offices in Buckingham and remotely around the UK. Details of any vacancies will be posted below.
e-Newsletter May 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Gene therapy shows promise in tackling X-linked RP
Early results from clinical testing of a gene therapy to treat X-linked retinitis pigmentosa (XLRP) have shown partial reversal of sight loss in some patients.
Retinal transplantation studies
Several groups around the world are investigating the use of retinal transplantation in the treatment of inherited retinal diseases.
Meet our volunteers: Steve and Khadeja
Steve has been volunteering for Retina UK since its formation in 1976 and has been a part of the Helpline team since the early 1980s.. He remembers very well a caller named Khadeja, who called the Helpline multiple times, following her diagnosis with RP in 1999.
Board of Trustees
Our Board of Trustees is responsible for the strategic management of the organisation and delivery of our charitable objectives.
Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Autosomal recessive inheritance
Autosomal recessive inheritance means that the faulty gene is on an autosome (any chromosome other than the sex chromosomes) and that both copies need to be faulty to cause sight loss
Genetics and gene therapy
When we talk about gene therapy we are usually referring to use of a harmless virus, called a vector, to deliver a normal copy of a defective gene into the cells of the eye.